MedTrace Logo

Follow-up of NAFLD Patients With MRI-PDFF

NCT04910178 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-12-20

No results posted yet for this study

Summary

The liver is a key organ in metabolism and contributes to T2DM development and insulin resistance via unclear mechanisms that may involve liver fat accumulation, inflammatory signals, and immune cells are proposed to play an important role in the pathogenesis of both NAFLD and T2DM.

Conditions

  • Diabetes Type 2
  • NAFLD

Interventions

DRUG

Empagliflozin 25 MG

tablets to be taken orally once a day

DRUG

Ursodeoxycholic acid

tablets to be taken orally twice a day

DRUG

Pentoxifylline 400 MG

tablets to be taken orally twice a day

OTHER

placebo

just starch tablets without any active agents

Sponsors & Collaborators

  • Asmaa Abdelfattah Elsayed

    lead OTHER

Principal Investigators

  • Asmaa A Elsayed, PhD · BUC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-12-01
Completion
2021-12-30
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910178 on ClinicalTrials.gov